Profile: Exelixis Inc (EXEL.O)
Exelixis, Inc. (Exelixis), incorporated in November 1994, is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications. The clinical program for cabozantinib is focused on the treatment of metastatic castration-resistant prostate cancer (CRPC) and medullary thyroid cancer but also includes the evaluation of other tumor types.
Cabozantinib inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth, vascularization and/or metastasis. As of December 31, 2011, the clinical program for cabozantinib is focused on the treatment of metastatic castration-resistant prostate cancer, and medullary thyroid cancer but also includes the evaluation of other tumor types. As of December 31, 2011, the Company had two phase 3 pivotal trials, COMET-1 (CabOzantinib MET Inhibition CRPC Efficacy Trial-1) and COMET-2 (CabOzantinib MET Inhibition CRPC Efficacy Trial-2), which were designed to provide an opportunity to commercially differentiate cabozantinib as an oncology agent with beneficial impact on overall survival, pain palliation and narcotic usage.
It focuses to generate data from the RDT, for cabozantinib in a broad range of tumor types, including ovarian cancer, melanoma, breast cancer, non-small cell lung cancer, hepatocellular cancer, renal cell carcinoma and differentiated thyroid cancer, to support further prioritization of its clinical and commercial options. In November 2011, the entered into a Cooperative Research and Development Agreement (CRADA), with National Cancer Institute’s Cancer Therapy Evaluation Program (CTEP) for evaluation of cabozantinib across multiple tumor types and in combination with other anti-tumor agents.
The Company has collaborations with pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Sanofi, Genentech, Inc. and Daiichi Sankyo Company Limited various compounds and programs in its portfolio. Pursuant to these collaborations, it has out-licensed compounds or programs to a partner for further development and commercialization. The Company is pursuing collaborations or other external opportunities for the continued development of its compounds and programs.
In December 2011, the Company entered into an agreement with Merck pursuant to which it granted Merck an exclusive worldwide license to its PI3K-d program, including XL499 and other related compounds. Pursuant to the terms of the agreement, Merck will have sole responsibility to research, develop, and commercialize compounds from our PI3K-d program.
The Company competes with AstraZeneca, Genentech, Pfizer, ArQule Inc. and GlaxoSmithKline.
210 E. GRAND AVE
SOUTH SAN FRANCISCO CA 94080